Search
3 articles for “Philadelphia-Chromosomes”
-
Cardiotoxicity Associated with Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Leukemias: An Overview of Mechanisms, Clinical Implications, and Management Strategies
Abstract: Tyrosine kinase inhibitors have greatly enhanced the outlook for individuals diagnosed with Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia and acute lymphoblastic leukemia. However, these therapeutic agents are associated with Cardiotoxicities and can manifest as left ventricular dysfunction, which may progress to heart failure, along with electrocardiographic abnormalities, dysrhythmias, hypertension, myocardial ischemia, and thromboembolic events. The unclear frequency of drug-induced cardiovascular complications, coupled with uncertainties regarding their reversibility and long-term …
Published in Research and Reviews: Journal of Oncology and Hematology · Vol. 13, Issue 3, 2024 · pp. 18–24 Read article
-
Extra Philadelphia in CML Due to Isodicentric 22: A Case Report
Abstract: Introduction: Chronic Myelogenous Leukemia is a malignancy that affects the hematopoietic stems cells (HSC) of the bone marrow, leading to the rapid and continual proliferation of granulocytes and precursor blast cells. This is caused due to a reciprocal translocation that occurs between chromosomes 9 and 22, leading to the formation of derivative 22 also called as Philadelphia (Ph) chromosome. The Ph chromosome then encodes a fusion oncoprotein that functions as …
Published in Research and Reviews: Journal of Oncology and Hematology · Vol. 14, Issue 3, 2025 · pp. 18–22 Read article
-
Dasatinib Induced Pulmonary Hypertension
Abstract: Dasatinib (Das) is a second-generation tyrosine kinase inhibitor that is used in the treatment of chronic myelogenous leukemia (CML) in patients who are resistant or intolerant to imatinib, as well as in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. Dasatinib-induced pulmonary arterial hypertension (PAH) is a known but rare adverse effect of dasatinib and is grouped under Group-1 PAH. The mechanism of PAH development is not fully known, but …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 14, Issue 3, 2024 · pp. 92–95 Read article